Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

5 Customer Reviews

  • Cell lines were exposed to the indicated concentrations of carboplatin (A) for 72 hours. Cell viability was assessed by alamarBlue assay and data recorded as fluorescence units at 590 nm. Data are presented as mean μM ± S.E.M. required to inhibit cell viability by 50%, in a minimum of three independent experiments.

    Cancer Lett, 2018, 436:75-86. Carboplatin purchased from Selleck.

    (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

  • Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

    A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlNk0zPeLCid88US=> NIfBWok4OiCq M2\JRolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NIfUTnozPjF|N{GwOS=>
Tca8113/CBP  MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDoc|EzNTJ34pEJ{txO Mm\1O|IhcA>? M1\EfIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M1nkeFI3OTN5MUC1
Tca8113/PYM  M2K1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPDNk0zPeLCid88US=> NFPyR2g4OiCq M3fse4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MkTRNlYyOzdzMEW=
SKOV3 NUnVNWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjDOlAhdWdxbXy= MoDTNU02KGR? NGfXS25qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTD0bY1mKGSncHXu[IVvfGy7 MlvqNlYyOzdyNEO=
SKOV3 NU\BN2N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Ob2VDOC12IN88[{9udA>? M{LueFI1NzR6L{eyJIg> NF;mfHVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NGnCW3gzPjF{NUK3Ny=>
SKOV3 M3TVNmFxd3C2b4Ppd{BCe3OjeR?= M3GyN|Ih|rypL33s MmqyOFghcA>? Mm\6bY5lfWOnczDhdI9xfG:|aYO= NFTxS5EzPjF{NUK3Ny=>
OSA M1PSbWNtd26xZ3XubYMhSXO|YYm= MVWyMlUwPSEQvF2= NEDRRlZz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 M131PVI3OTFyNkKw
A549 NV;Yb5h7TnWldHnvckBCe3OjeR?= NF3pbnIxNzJ3L{WwJO69VQ>? NWfLWZZrOjRiaB?= Mnvr[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= MXSyOVkyPzNzNx?=
H1975 MV;GeYN1cW:wIFHzd4F6 NWXm[G5HOC9{NT:1NEDPxE1? MYKyOEBp NXrudpRu\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NUn0OXRrOjV7MUezNVc>
A549 M1PlfGZ2[3Srb36gRZN{[Xl? M3jzXFAwOjVxNUCg{txO NWPSUZdpOjRiaB?= M4XiU5VxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? MnfPNlU6OTd|MUe=
H1975 MYLGeYN1cW:wIFHzd4F6 M1iwe|AwOjVxNUCg{txO M{XLZ|I1KGh? NHHOd4h2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? NH3DU48zPTlzN{OxOy=>
A549 NEWwRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rtelI2KM7:TR?= NVPY[VV2OjRiaB?= M{TGVYlvcGmkaYTzJINmdGxiZ4Lve5Rp M{PWOFI2QTF5M{G3
H1975 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor6NlUh|ryP M1j1V|I1KGh? M3\TSYlvcGmkaYTzJINmdGxiZ4Lve5Rp MnPFNlU6OTd|MUe=
MDA-MB-231 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG1flYxNTJ{MDFOwIcwdWx? MmXjO|IhcA>? NYDkSJZNUUN3MNMgQUA5PiEQvF2= MmrpNlU5Ozd4OUG=
T47D MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS4UFNvOC1{MkCg{txoN22u M{LFdFczKGh? NWnEbWpqUUN3MNMgQUA1QC57IN88US=> M2nq[VI2QDN5Nkmx
LCTCC MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXLTWM2OD1|LklihKnDvU1? Mn:4NlU4PzNzNke=
MCTCC M2LXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PMcmlEPTB;Mj645qCKyrWP NFTkV2gzPTd5M{G2Oy=>
MegTCC NVrNXYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC0NGtKSzVyPUSuNgKBkcL3TR?= MWCyOVc4OzF4Nx?=
MonoTCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTVwNvMAjeK2VQ>? NXS0SHQ6OjV5N{OxOlc>
MCF7 M{XGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zFWFIxKM7:TR?= NWXHXYF{PzJiaB?= MkmzbY5lfWOnczDj[YxtKGSnYYToJI9nKEiSMd8yMYRmeGyndHXkJG1ETjdiY3XscJM> NH\rcHIzPTd4OUCyOS=>
A-549  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMlUh|ryP MUGyOEBp MkOwSG1UV8Li Ml7WbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NVfFW|lEOjV5NUW2PVA>
A-549  M1HIT2Fxd3C2b4Ppd{BCe3OjeR?= MV:wMlUh|ryP NGnOeGU1QCCq NGLlSY1FVVORwrC= MkSxd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? MXeyOVc2PTZ7MB?=
A-549  NWjyeGlbTnWldHnvckBCe3OjeR?= NFP3TY8xNjVizszN M{T4N|Q5KGh? MlTOSG1UV8Li MlvKd4hwf3NiYXLldpJidnRibXnjdo91fWK3bHWg[Il{enWydHnvci=> MmrjNlU4PTV4OUC=
A-549  MlTKSpVkfGmxbjDBd5NigQ>? NYj5NmdSOC53IN88US=> NX2y[3g{PDhiaB?= NYnRR3dSTE2VT9Mg M3LpSYlvcGmkaYTzJI9nKGOnbHygcYloemG2aX;uxsA> MlP3NlU4PTV4OUC=
RMG-1 NIXCUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTacmJKSzVyPUK4MlghyrFiMz62JI1oN0x? Moi4NlU4OjZ7MUO=
FN-RMG-1 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7qTWM2OD12MD61JOKyKDRwMjDt[{9NEiEQvF2= MXyyOVczPjlzMx?=
RMG-1-hFUT Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTV6LkGgxtEhOi52IH3nM2w> NWHzPXVbOjV5Mk[5NVM>
FN-RMG-1-hFUT MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFzOD64JOKyKDF|LkigcYcwVA>? MlSwNlU4OjZ7MUO=
CHP-134  MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDTNmIyKM7:TR?= Mn\mSG1UV8Li NUnqRnNncW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz NVy1OYNbOjV4NUi0OlM>
IMR-32 NWjOSohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxJO69VQ>? MnfRSG1UV8Li MkLKbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy NWj6NW5yOjV4NUi0OlM>
CHP-134  NV3UbW9[TnWldHnvckBCe3OjeR?= NUfjcVBCOTBizszNxsA> MX3EUXNQyqB? NWfxNFF4cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? M1n5[VI2PjV6NE[z
IMR-32 NIKxbHdHfWO2aX;uJGF{e2G7 NH\BSYIyOCEQvF5CpC=> NFHSeZJFVVORwrC= MX3pcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh|MEO3NS=> NVS4ZpliOjV4NUi0OlM>
A549 NUjrZZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHjNE4zNTRyMECg{txO NU\N[|ZmPzJiaB?= M2DwPGlEPTB;MUK2JOKyKDVwMDFOwG0> M1faSFI2PjJ3MkSz
A549/CDDP MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrzdlMxNjJvNECwNEDPxE1? MoTYO|IhcA>? NUPBfphbUUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= MUKyOVYzPTJ2Mx?=
H460  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TPOFI1KGh? MWHEUXNQ Mkf2TWM2OD15Lkmg{txO NXrMeZpDOjV3OUm5PVU>
H460  MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC3Mlkh|ryP MWmyOEBp MW\EUXNQ NX;lZ|M6e2ixd4OgZUBz[WSrb4PlcpNqfGm8aX7nJIVn\mWldDD0c{BZNXKjeYO= MnLBNlU2QTl7OUW=
NRK-52E NYf1coo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[2fnFzPzMEoHlCpC=> MnvXTWM2OD1zMECgxtEhOTJwOTFOwG0> Mme3NlU2PjV4MEO=
RGE NHLBS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixO49jPzMEoHlCpC=> MoPHTWM2OD1{MjFCtUA4NjRizszN MWmyOVU3PTZyMx?=
NRK-52E NYLXbIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmzb2hqPzMEoHlCpC=> M{XkRmlEQDB;MUe5JOKyKDlwNTFOwG0> MljDNlU2PjV4MEO=
RGE M4PlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7DOlY4OsLiaNMg M1rwZWlEQDB;NkOgxtEhPy52IN88US=> MXmyOVU3PTZyMx?=
SK-OV-3 MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp Mln4TWM2OD1zMESuPEDPxE1? NH3KR3gzPTV{MEGzNi=>
ES-2 M3L1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHMTGk4OiCq MULJR|UxRTF2Lk[g{txO NYfq[WV2OjV3MkCxN|I>
OVCAR-8 NYe4UXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nH[lczKGh? M1;ETWlEPTB;OU[uNEDPxE1? MVeyOVUzODF|Mh?=
3AO MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH0Sng4OiCq NX;ERohxUUN3ME22N{41KM7:TR?= MlO2NlU2OjBzM{K=
A2780 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjP[o1JPzJiaB?= Mn:xTWM2OD1zNEWuO{DPxE1? MWmyOVUzODF|Mh?=
SW626 NVr1SoZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkezO|IhcA>? NILJemNKSzVyPUm3MlAh|ryP NWXSdXlvOjV3MkCxN|I>
OVCAR-3 NGHhNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLvSHdpPzJiaB?= M1;Oc2lEPTB;M{KuOkDPxE1? M17CcVI2PTJyMUOy
A549 NIDwPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXqeFFiUUN3ME2xOVEvPTZiwsGgOVMvODZizszN M2nl[FI2Ojd5NE[x
4T1 M2DPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnrbZlIUUN3ME24OE43OiEEsTCzNE4xPSEQvF2KJO69VQ>? NUPtWWcyOjV{N{e0OlE>
BALB/3T3 M4Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTVTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>? NHLLO5kzPTJ5N{S2NS=>
B16 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPad|lKSzVyPU[0MlMxKMLzIE[uPFEh|ryP MVqyOVI4PzR4MR?=
DU 145 NXLzSVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3iUI1KSzVyPUO1MlA1KMLzIEG3MlU1KM7:TR?= Ml\HNlUzPzd2NkG=
FaDu MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXxSVhyUUN3ME20OU4{QSEEsTCxNU42OCEQvF2= NFS1PWYzPTJ5N{S2NS=>
HCV-29T NHz1e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnKZZhKSzVyPUS4MlU4KMLzIEKyMlQ6KM7:TR?= NUXBeWpDOjV{N{e0OlE>
HL-60 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj3d5N1UUN3ME2xNU4yOCEEsTC0MlQ4KM7:TR?= NEnyZlMzPTJ5N{S2NS=>
HT-29 NH\5SYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe5OGpKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= M1;UZVI2Ojd5NE[x
H146 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f2WmlEPTB;NEmuOuKyOTNwMTFOwG0> MUKyOVEzPDJ6Mh?=
H187 NFTFNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzSPYI2UUN3ME2xNk44yrF{Lkeg{txO NFzL[JgzPTF{NEK4Ni=>
H128 NEHKWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z3bWlEPTB;MUC2MlTDuTlwNjFOwG0> MofJNlUyOjR{OEK=
H69 NYjFcI84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX6TWM2OD15Nj65xtEzPy56IN88US=> NEnOc2wzPTF{NEK4Ni=>
H209 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLSeGNKSzVyPUK1PE4yyrF7OT64JO69VQ>? NIPCWZMzPTF{NEK4Ni=>
DMS153 NFnDfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3KTWM2OD13Nz64xtE6NjJizszN MlTFNlUyOjR{OEK=
H526 NIfwPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTdwMtMxNU44KM7:TR?= NHT4UpczPTF{NEK4Ni=>
DMS114 M1nrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz4VG1KSzVyPUi1MljDuTF{Lkig{txO MlrWNlUyOjR{OEK=
DMS53 M3LCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXBRo5KSzVyPUG0Ok4zyrF|Nj60JO69VQ>? MWmyOVEzPDJ6Mh?=
HeLa NUDqcoFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHvT4E2NThyIN88US=> M3Hoc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3TjVFI2OTB7M{[w
MCF-7 NGXWPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;GN4VKPS16MDFOwG0> NIXTZndqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NY\ZcIg4OjVzMEmzOlA>
MDA-MB-231 NGP2VIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF21NW42NThyIN88US=> MmXTbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1W3WFI2OTB7M{[w
CaOV3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33QZ|czKGh? MnrJTWM2OD16Nj6xJO69VQ>? MWeyOVA3QDh2OR?=
OVCAR-3 NUK1PY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnFO|IhcA>? NX\ud5QxUUN3ME2xO|kvPSEQvF2= MYSyOVA3QDh2OR?=
OVCAR-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS3NkBp MVnJR|UxRTd3Lkeg{txO NXG3T3RjOjVyNki4OFk>
SKOV-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LOZVczKGh? MX7JR|UxRTVyNDFOwG0> M2HGV|I2ODZ6OES5
OVCAR-4 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy3NkBp NEfXN3VKSzVyPUK5NE43KM7:TR?= MnvSNlUxPjh6NEm=
OVCAR-8 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrXWmc4OiCq NUfPfZVZUUN3ME22PVAvOiEQvF2= NXzJZ4hlOjVyNki4OFk>
MA148 M37rUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILRW3QzPCCq Ml\RTWM2OD16Mz625qCKyrIkgJmxMlQh|rypL33s MmH6NlQ5OzFyOUG=
A549 NUjVVnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe3ZoUzPCCq MXjJR|UxRTd5Nj6w5qCKyrIkgJmxMlkh|rypL33s NUfEZpVwOjR6M{GwPVE>
MDA-MB-231 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfE[owzPCCq NWm4dWZ{UUN3ME23OFgvOOLCidMx5qCKOS5zIN88[{9udA>? MXmyOFg{OTB7MR?=
NCI-ADR/RES  M3;jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKyOEBp NY\WOJhpUUN3ME2xO|U{NjEkgJpCtgKBkTRwNDFOwIcwdWx? M4rCTVI1QDNzMEmx
MA148 NFnsNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYq0PEBp MkHoTWM2OD1{OD6x5qCKyrIkgJmxMlAh|rypL33s M2f0bVI1QDNzMEmx
A549 NYLo[3FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS0PEBp M3XISmlEPTB;MUG4MlDjiIoEsfMAjVEvOiEQvHevcYw> NHjEZoUzPDh|MUC5NS=>
MDA-MB-231 NHPEWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H4UFQ5KGh? NVjM[pdDUUN3ME2xPFMvOOLCidMx5qCKOS5{IDFOwIcwdWx? M2LPSVI1QDNzMEmx
NCI-ADR/RES  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\tW405PDhiaB?= NID1VFVKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t M4rFTFI1QDNzMEmx
MA148 NIDEVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnjdI9{PzJiaB?= NX\zPIJiUUN3ME2xN{446oDLwsJihKkyNjJizsznM41t M1q0cVI1QDNzMEmx
A549 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrGcnc4OiCq NIS4bG9KSzVyPU[0MlPjiIoEsfMAjVEvOSEQvHevcYw> MoLRNlQ5OzFyOUG=
MDA-MB-231 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDPO|IhcA>? NV;LUHNHUUN3ME25PU426oDLwsJihKkyNjFizsznM41t M1\OclI1QDNzMEmx
NCI-ADR/RES  MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHmNZY4OiCq M3vvO2lEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=> Mn\ONlQ5OzFyOUG=
A549 M4rrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfD[lY4OiCq NXKyWZJOTE2VTx?= NYj3PIZ3UUN3ME2xOVIvPDB7IN88US=> NH;6UG8zPDd{MUOyNy=>
NCI-H157 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HTXlczKGh? MUfEUXNQ NWjsbZdsUUN3ME24PU46PzdizszN NYPxcFhYOjR5MkGzNlM>
PC9 NX\QZ4ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;Veoc4OiCq MXfHR|UxRTdzLkdCtVkvPSEEtV2= NFe0ZoUzPDZzOEiwPS=>
A549  NHn0bmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H5WFczKGh? MlXuS2M2OD1zM{dCtVMyNjZiwsXNxsA> M2G4TFI1PjF6OEC5
PC9 NYHUS2hFSXCxcITvd4l{KEG|c3H5 M1;t[VExOCEEtV2= MXy3NkBp MUfpcoR2[2W|IHHwc5B1d3Orcx?= MkjHNlQ3OTh6MEm=
A549  M4LST2Fxd3C2b4Ppd{BCe3OjeR?= MmfJNVAxKML3TR?= MXu3NkBp NFLXfnRqdmS3Y3XzJIFxd3C2b4Ppdy=> NULZRnc4OjR4MUi4NFk>
A549 M{mxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTtNlQhcA>? MnK1TWMyOD1zLkS3OkBvVQ>? M1nzWFI1Ozl4NEO3
H1299 NUj2cGxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fLe|I1KGh? NYjwOmxjUUNzME2wMlQ1OyCwTR?= MVKyOFM6PjR|Nx?=
HCC15 NVe0XVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXySHMzPCCq M2nGTmlEOTB;MD6zOFYhdk1? MYSyOFM6PjR|Nx?=
H157 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXqUXYzPCCq NGTSPZpKSzFyPUCuPFEhdk1? NWm1dWtYOjR|OU[0N|c>
A2780 NIPuOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? NHLzd4gzPDJyOU[5Ny=>
A2780cisR M1;5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD12OD655qCKyrIkgJmzMlkh|ryP NYnIVFByOjR{MEm2PVM>
A2780ZD0473R MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rFdmlEPTB;NkSuOwKBkcLz4pEJN{4zKM7:TR?= NF;p[pEzPDJyOU[5Ny=>
SKOV-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrmTWM2OD12Mz605qCKyrIkgJmzMlkh|ryP M1u0[VI1OjB7Nkmz

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
in solvent
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT02487849 Suspended Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer Krankenhaus Barmherzige Schwestern Linz August 2019 Phase 2
NCT02487849 Suspended Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer Krankenhaus Barmherzige Schwestern Linz August 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID